Evolving Practice Patterns for Clear Cell Renal Cell Carcinoma
A discussion regarding the potential implications of treating renal cell carcinoma based on recent clinical trial data and key presentations from the 2021 ASCO virtual meeting.
Advertisement
Evolving Practice Patterns for Clear Cell Renal Cell Carcinoma
Dr. Sandy Srinivas comments on treatment approaches for frontline metastatic renal cell carcinoma based on the emergence of novel combination regimens that introduce immunotherapy.
Amishi Y. Shah, MD, comments on the significance of updated survival data revealed by the CheckMate 214 study using the combination of ipilimumab plus nivolumab as frontline therapy for metastatic renal cell carcinoma.
Thomas Powles, MD, MBBS, MRCP, describes the KEYNOTE-426 trial in frontline metastatic renal cell carcinoma and comments on the use of pembrolizumab plus axitinib for appropriate patients.
Robert S. Alter, MD, provides key takeaways from the CheckMate 9ER study of nivolumab plus cabozantinib as frontline therapy for patients with metastatic renal cell carcinoma.
Characteristics that distinguish the CLEAR trial of lenvatinib plus pembrolizumab as frontline therapy for metastatic renal cell carcinoma from other pivotal trials of immunotherapy plus tyrosine kinase inhibitors.
Variables that impact one’s decision to treat metastatic renal cell carcinoma with an immunotherapy-based regimen that includes a targeted agent vs additional immunotherapy.
Dr Amishi Y. Shah, of MD Anderson Cancer Center, describes the rationale for active surveillance vs treatment with a novel therapeutic in metastatic renal cell carcinoma.
Considerations for how to approach a patient with metastatic renal cell carcinoma previously treated with ipilimumab and nivolumab, followed by nivolumab maintenance.
Expectations regarding the impact of research in metastatic renal cell carcinoma on the use of immunotherapy and targeted agents in routine clinical practice.
